Ultra-Low-Dose Induction Advances Peanut and Walnut OIT

Ultra-low-dose induction therapy may allow children with severe peanut and walnut allergies to initiate conventional oral immunotherapy, according to an observational cohort study. The multicenter study examined 21 pediatric patients older than 3 years who had physician-diagnosed severe peanut or walnut allergies. Participants faced extreme reaction thresholds, presenting histories of Grade 2 or higher allergic reactions, including anaphylaxis, or reactions to trace amounts of the allergens. These severe sensitivities had previously prevented them from starting or progressing through conventional oral immunotherapy protocols.

Evaluating Ultra-Low-Dose Protocols for Pediatric Nut Allergies

Researchers collected data between 2021 and 2024 to evaluate the safety and feasibility of the ultra-low-dose induction phase. Participants were divided into a peanut allergy group and a walnut allergy group. Investigators determined individual starting doses using serial 5-fold dilutions of allergen extracts. Patients ingested their selected extract dose twice daily for one month. During monthly clinic visits, medical staff increased the doses by adding drops and advancing to more concentrated extract dilutions as patients tolerated them.

All peanut allergy participants and 90.9% of walnut allergy participants successfully transitioned to conventional oral immunotherapy. These patients tolerated milligram-level powder ingestion. The median time required to transition was 16 months for the peanut group and 8 months for the walnut group. Most children tolerated higher doses during subsequent allergen-drop challenges.

Patients Tolerate Commercial Products with Rare Adverse Reactions

Adverse reactions during home-based drop maintenance were rare, occurring at rates of 0.02% for peanuts and 0.09% for walnuts. Researchers noted that these reactions were mostly mild to moderate, and no patient required adrenaline at any stage of the treatment protocol. Following the induction phase, 30% of patients with peanut allergies and 27.3% of patients with walnut allergies could consume commercial products containing the allergens.

Study authors suggested that the therapeutic benefits extend beyond raising reaction thresholds. The protocol may also alleviate the daily anxiety that families experience regarding accidental allergen exposure. The researchers concluded that ultra-low-dose induction successfully bridges the gap for highly sensitive children, helping them reach milligram-level protein tolerance.

Lack of Randomized Group Requires Further Scientific Study

Despite the positive transition rates, the study authors noted several methodological limitations. The observational cohort investigation lacked a randomized comparison group and utilized non-standardized allergen extracts. Consequently, the research team emphasized that further scientific study is required to confirm these findings across broader patient populations before clinical guidelines change.